RxDoctor Payments Data

Gabrielle Sundholm, PA

Physician Assistant · Raleigh, NCNPI 1063925451

Payments from drug & device makers

$3,030in general payments, 2019–2025

Across 101 payments — averaging $30.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$351
  • Esperion Therapeutics, Inc.$349
  • Alnylam Pharmaceuticals Inc.$314
  • Boehringer Ingelheim$285
  • Novartis$275
  • Irhythm Technologies, Inc.$265
  • plus $1K from 14 others

What the payments were for

  • Grants$1003%
  • Food & beverage$2,93097%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,030 in reported general payments places this provider in the 85th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$63,566
Medicare patients
427
Services billed
829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban420$399,142
EntrestoSacubitril/Valsartan113$112,278
XareltoRivaroxaban52$56,476
BrilintaTicagrelor40$27,551
JardianceEmpagliflozin22$25,269
Repatha SureclickEvolocumab28$19,746
FarxigaDapagliflozin Propanediol20$16,748
Ranolazine ErRanolazine97$9,549
Dofetilide33$8,195
Metoprolol Succinate352$4,954
Losartan Potassium209$2,502
Prasugrel Hcl48$2,414
Atorvastatin Calcium185$2,411
Droxidopa12$2,387
Isosorbide Mononitrate ErIsosorbide Mononitrate171$2,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$399,142420 claims
NovartisEntresto$275$112,278113 claims
Johnson & JohnsonXarelto$173$56,47652 claims
AstraZenecaBrilinta, Farxiga$252$44,29960 claims
Boehringer IngelheimJardiance$285$25,26922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →